Grufity logoGrufity logo

NRIX

11.86USD-0.03(-0.25%)Delayed

Nurix Therapeutics, Inc.

Market Summary

USD11.86-0.03Delayed
-0.25%

NRIX Stock Price

RSI Chart

Valuation

Market Cap

603.5M

Price/Earnings

-3.91

Price/Sales

15.6

Price/Cashflow

-4.42

MarketCap/EBT

-3.91

Price/Sales

Profitability

EBT Margin

-399.34%

Return on Equity

-57.91%

Return on Assets

-39.18%

Fundamentals

Revenue

Revenue (TTM)

38.7M

Revenue Y/Y

61.22%

Revenue Q/Q

18.82%

Earnings

Earnings (TTM)

-154.5M

Earnings Y/Y

-72.09%

Earnings Q/Q

-6.74%

Price Action

52 Week Range

32.18
(Low)(High)

Last 7 days

-8.8%

Last 30 days

-1.7%

Last 90 days

-23.1%

Trailing 12 Months

-61.4%

Financial Health

Current Ratio

4.22

Investor Care

Shares Dilution (1Y)

5.89%

Diluted EPS (TTM)

-3.46

Peers (Alternatives to Nurix Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
2.4T
394.3B
-0.67% -8.01%
23.66
5.99
7.79% 5.41%
1.8T
203.1B
7.29% -26.07%
25.2
8.66
15.22% 2.81%
1.3T
282.1B
2.93% -33.48%
18.7
4.44
17.94% -5.14%
952.9B
502.2B
-19.24% -47.82%
84.16
1.9
9.66% -56.89%
MID-CAP
2.5B
8.6B
6.97% -44.81%
-5.69
0.31
76.30% -20.89%
SMALL-CAP
1.9B
628.4M
4.90% -64.68%
-4.08
3.1
64.35% -18.14%
1.9B
1.6B
1.73% 6.73%
12.45
1.23
81.91% 208.48%
1.5B
-
15.46% -69.17%
-0.54
1.95
-4.11% -144.36%
1.4B
40.0M
-23.89% -77.58%
-1.84
34.64
34.91% -55.12%
1.0B
247.8M
5.73% -20.09%
-17.78
4.46
23.41% -194.70%
1.0B
412.4M
16.46% -28.89%
-153.63
2.47
51.09% -102.33%
988.1M
439.7M
-14.05% -83.16%
-2.97
2.13
-5.64% -199.38%
861.5M
1.2B
1.09% -47.19%
2.31
0.73
7.66% 583.60%
551.2M
2.2M
2.03% -70.95%
-1.55
343.43
-72.60% -50.32%

Financials for Nurix Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue12.6%3934302923
Operating Expenses13.9%194170148129113
  S&GA Expenses6.3%3634312925
  R&D Expenses15.7%15813711610088
Earnings Before Taxes-14.2%-154.55-135.39-117.06-99.28-88.84
Net Income-14.0%-154.47-135.45-117.19-99.41-89.09
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-9.9%394438477493518
  Current Assets9.4%307280311358396
    Cash Equivalents-47.3%427981147188
  Net PPE14.7%161411108
Liabilities-3.2%128132134118120
  Current Liabilities10.0%7366665147
Shareholder's Equity-12.8%267306342375398
  Retained Earnings-17.2%-308.80-263.40-220.90-183.20-154.35
  Additional Paid-In Capital1.3%579571564558552
Accumulated Depreciation6.3%1716151414
Shares Outstanding0.4%4545454544
Float-1,100----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-1.0%-136.46-135.08-84.40-73.94-50.10
  Share Based Compensation14.8%2219161310
Cashflow From Investing79.5%-13.49-65.83-108.25-196.29-292.14
Cashflow From Financing-97.4%4154154152371

Risks

What is the probability of a big loss on NRIX?

91.9%


Probability that Nurix Therapeutics stock will be more than 20% underwater in next one year

87.8%


Probability that Nurix Therapeutics stock will be more than 30% underwater in next one year.

66.7%


Probability that Nurix Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NRIX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Nurix Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on NRIX

Which funds bought or sold NRIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
18,000
617,000
-%
2022-11-15
FRED ALGER MANAGEMENT, LLC
SOLD OFF
-100
-93,000
-
-%
2022-11-15
NOMURA HOLDINGS INC
REDUCED
-61.08
-5,023,000
3,101,000
0.01%
2022-11-15
Balyasny Asset Management LLC
NEW
-
208,000
208,000
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
ADDED
13.16
152,000
1,080,000
-%
2022-11-15
ALGERT GLOBAL LLC
ADDED
50.83
104,000
294,000
0.02%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
ADDED
27.43
231,000
974,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
NEW
-
995,687
995,687
-%
2022-11-15
JACOBS LEVY EQUITY MANAGEMENT, INC
NEW
-
167,000
167,000
-%

1–10 of 47

Latest Funds Activity

Are funds buying NRIX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own NRIX

Nurix Therapeutics News

The News Heater

Is There a Dimmer Outlook Ahead for Nurix Therapeutics Inc. (NRIX)?.47 hours ago

GuruFocus.com

NRIX Fair Value

Recent SEC filings of Nurix Therapeutics

View All Filings
Date Filed Form Type Document
Nov 01, 2022
4
Insider Trading
Nov 01, 2022
4
Insider Trading
Nov 01, 2022
4
Insider Trading
Nov 01, 2022
4
Insider Trading
Oct 26, 2022
8-K
Current Report
Oct 06, 2022
10-Q
Quarterly Report
Oct 06, 2022
8-K
Current Report
Sep 14, 2022
3
Insider Trading
Sep 14, 2022
4
Insider Trading
Sep 14, 2022
8-K
Current Report

Latest Insider Trading transactions for NRIX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-31
Hansen Gwenn
SOLD
-15,005.8
12.8805
-1,165
Chief Scientific Officer
2022-10-31
Wolff Stefani
SOLD
-4,508.17
12.8805
-350
EVP and COO
2022-10-31
Ring Christine
SOLD
-9,003.47
12.8805
-699
General Counsel
2022-10-31
van Houte Hans
SOLD
-9,518.69
12.8805
-739
Chief Financial Officer
2022-10-30
Hansen Gwenn
ACQUIRED
-
-
3,207
Chief Scientific Officer
2022-10-30
Ring Christine
ACQUIRED
-
-
1,924
General Counsel
2022-10-30
Wolff Stefani
ACQUIRED
-
-
962
EVP and COO
2022-10-30
van Houte Hans
ACQUIRED
-
-
2,886
Chief Financial Officer
2022-08-01
Hansen Gwenn
SOLD
-18,584.6
15.67
-1,186
Chief Scientific Officer
2022-08-01
Wolff Stefani
SOLD
-5,578.52
15.67
-356
EVP and COO

1–10 of 50

Arthur T. Sands
240
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

NRIX Income Statement

2022-05-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended6 Months Ended
May 31, 2022
May 31, 2021
May 31, 2022
May 31, 2021
Income Statement [Abstract]    
Collaboration revenue$ 11,432,000$ 7,091,000$ 21,053,000$ 12,102,000
Operating expenses:    
Research and development47,493,00025,994,00090,630,00048,997,000
General and administrative9,654,0007,511,00018,882,00014,041,000
Total operating expenses57,147,00033,505,000109,512,00063,038,000
Loss from operations(45,715,000)(26,414,000)(88,459,000)(50,936,000)
Interest and other income, net314,000171,000525,000489,000
Loss before income taxes(45,401,000)(26,243,000)(87,934,000)(50,447,000)
Provision for income taxes0139,0000210,000
Net loss$ (45,401,000)$ (26,382,000)$ (87,934,000)$ (50,657,000)
Net loss per share, basic$ (1.01)$ (0.60)$ (1.96)$ (1.23)
Weighted-average number of shares outstanding, basic44,898,40943,804,06644,797,23541,318,281
Net loss per share, diluted$ (1.01)$ (0.60)$ (1.96)$ (1.23)
Weighted-average number of shares outstanding, diluted44,898,40943,804,06644,797,23541,318,281

NRIX Balance Sheet

2022-05-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
May 31, 2022
Nov. 30, 2021
Current assets:  
Cash and cash equivalents$ 41,533$ 80,506
Short-term investments255,746215,214
Accounts receivable 6,000
Income tax receivable 204
Prepaid expenses and other current assets9,5109,194
Total current assets306,789311,118
Long-term investments51,538137,189
Operating lease right-of-use assets15,41814,005
Property and equipment, net15,50711,340
Restricted cash901286
Other assets4,1572,833
Total assets394,310476,771
Current liabilities:  
Accounts payable6,1426,650
Accrued expenses and other current liabilities19,73414,549
Operating lease liabilities, current5,4703,847
Deferred revenue, current41,31941,212
Total current liabilities72,66566,258
Operating lease liabilities, net of current portion9,0439,189
Deferred revenue, net of current portion45,86359,022
Total liabilities127,571134,469
Commitments and contingencies (Note 6)
Stockholdersʼ equity:  
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2022 and November 30, 2021; no shares issued and outstanding as of May 31, 2022 and November 30, 2021
Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2022 and November 30, 2021; 45,040,068 and 44,664,371 shares issued and outstanding as of May 31, 2022 and November 30, 2021, respectively4545
Additional paid-in capital578,605563,757
Accumulated other comprehensive loss(3,085)(608)
Accumulated deficit(308,826)(220,892)
Total stockholdersʼ equity266,739342,302
Total liabilities and stockholdersʼ equity$ 394,310$ 476,771